Open AccessCarbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance
Author(s) -
Alina Iovleva,
Mustapha M. Mustapha,
M. Patrick Griffith,
Lauren Komarow,
Courtney Luterbach,
Daniel R. Evans,
Eric Cober,
Sandra Richter,
Kirsten Rydell,
César A. Arias,
Jesse T Jacob,
Robert A. Salata,
Michael J. Satlin,
Darren Wong,
Robert A. Bonomo,
David van Duin,
Vaughn S. Cooper,
Daria Van Tyne,
Yohei Doi
Publication year - 2022
Publication title -
mbio
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.562
H-Index - 121
eISSN - 2161-2129
pISSN - 2150-7511
DOI - 10.1128/mbio.02759-21
Subject(s) - acinetobacter baumannii , carbapenem , molecular epidemiology , microbiology and biotechnology , antibiotic resistance , antimicrobial , acinetobacter , epidemiology , antibiotics , biology , medicine , bacteria , genetics , pseudomonas aeruginosa , genotype , gene
Carbapenem-resistantAcinetobacter baumannii (CRAb ) constitutes a major threat to public health. To elucidate the molecular and clinical epidemiology of CRAb in the United States, clinical CRAb isolates were collected along with data on patient characteristics and outcomes, and bacterial isolates underwent whole-genome sequencing and antibiotic susceptibility phenotyping.